Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor

References

• Committee CS, Others. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet. 1996;348(9038):1329–1339.
   PubMed Web of Science ®Google Scholar
• Pride YB, Wiviott SD, Buros JL, Zorkun C, Tariq MU, Antman EM, et al. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 substudy. Am Heart J. 2009;158(3):e21–6.
   PubMed Web of Science ®Google Scholar
• James S, Åkerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2009;157(4):599–605.
   PubMed Web of Science ®Google Scholar
• The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Programme. Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21(24):2033–2041.
   PubMed Web of Science ®Google Scholar
• Authors/Task Force Members, Kolh P, Windecker S, Alfonso F, Collet J-P, Cremer J, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) * Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardio-Thoracic Surg. 2014;46(4):517–592.
   PubMedGoogle Scholar
• Gurbel Pa, Tantry Us. Clopidogrel resistance? Thromb Res. 2007;120(3):311–321.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2017;2017(Aug):26.
   Google Scholar
• Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209–215.
   PubMed Web of Science ®Google Scholar
• Harrison P. Advances in the monitoring of anti-P2Y12 therapy. Platelets. 2012;23(7):510–525.
   PubMed Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62(24):2261–2273.
   PubMed Web of Science ®Google Scholar
• Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation. J Thromb Haemost. 2009; 717–20.
   PubMed Web of Science ®Google Scholar
• Hollopeter G, Jantzen H-M, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202–207.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Storey RF. The future of P2Y12 receptor antagonists. Platelets. 2015;26(5):392–398.
   PubMed Web of Science ®Google Scholar
• Le Quellec S, Bordet J-C, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response review literature. Thromb Haemost. 2016;116(4):638–650.
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Geiger J, Walter U, Eigenthaler M. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets–definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost. 1999;82(3):1145–1152.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost. 2013;11(6):1183–1189.
   Web of Science ®Google Scholar
• Barragan P, Bouvier J-L, Roquebert P-O, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheteriz Cardiovasc Interv. 2003;59(3):295–302.
   PubMed Web of Science ®Google Scholar
• Zhang H-Z, Yu LH, Kim MH. Effect of different anticoagulants on multiple electrode platelet aggregometry after clopidogrel and aspirin administration in patients undergoing coronary stent implantation: a comparison between citrate and hirudin. Platelets. 2013;24(5):339–347.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, et al. Spontaneous MI after non–ST-segment elevation acute coronary syndrome managed without revascularization. J Am Coll Cardiol. 2016;67(11):1289–1297.
   PubMed Web of Science ®Google Scholar
• Collet J-P, Cayla G, Cuisset T, Elhadad S, Rangé G, Vicaut E, et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J. 2011;161(1):5–12.e5.
   PubMed Web of Science ®Google Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation. 2011;124(10):1132–1137.
   PubMed Web of Science ®Google Scholar
• Christ G, Siller-Matula JM, Francesconi M, Dechant C, Grohs K, Podczeck-Schweighofer A. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry. BMJ Open. 2014;4(10):e005781.
   PubMed Web of Science ®Google Scholar
• Capranzano P, Capodanno D, Bucciarelli-Ducci C, Gargiulo G, Tamburino C, Francaviglia B, et al. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care. 2016;5(5):475–486.
   PubMed Web of Science ®Google Scholar
• Godschalk TC, Byrne RA, Adriaenssens T, Malik N, Feldman LJ, Guagliumi G, et al. Observational study of platelet reactivity in patients presenting with ST-segment elevation myocardial infarction due to coronary stent thrombosis undergoing primary percutaneous coronary intervention: results from the European Prevention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry. JACC Cardiovasc Interv. 2017;10(24):2548–2556.
   PubMed Web of Science ®Google Scholar
• Gachet C, Aleil B. Testing antiplatelet therapy. Eur Heart J Suppl. 2008;10(Suppl A):A28–34.
   Web of Science ®Google Scholar
• Paniccia R, Priora R, Alessandrello Liotta A, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133–148.
   PubMed Web of Science ®Google Scholar
• Bagoly Z, Sarkady F, Magyar T, Kappelmayer J, Pongrácz E, Csiba L, et al. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. Schulz C, editor. PLoS One. 2013;8(7):e69417.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, et al. Clopidogrel response status assessed with multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost. 2009;103(1):151–159.
   PubMed Web of Science ®Google Scholar
• Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost. 2006;96:781–788.
   PubMed Web of Science ®Google Scholar
• Calatzis A, Spannagl M, Loreth R. Multiplate® platelet function analysis - application and interpretation; Munich: Munich University. 2007.
   Google Scholar
• Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100® system using the new test cartridge INNOVANCE® PFA P2Y. Ann Hematol. 2010;89(6):597–605.
   PubMed Web of Science ®Google Scholar
• Koessler J, Kobsar AL, Rajkovic MS, Schafer A, Flierl U, Pfoertsch S, et al. The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition. Platelets. 2011;22(1):19–25.
   Web of Science ®Google Scholar
• Jeong Y-H, Bliden KP, Tantry US, Gurbel PA. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low?: letters to the Editor. J Thromb Haemost. 2012;10(3):487–489.
   PubMed Web of Science ®Google Scholar
• Ghannudi SE, Ohlmann P, Meyer N, Wiesel M-L, Radulescu B, Chauvin M, et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty. JACC Cardiovasc Interv. 2010;3(6):648–656.
   PubMed Web of Science ®Google Scholar